Home | Log In | Register | Our Services | My Account | Contact | Help |
Shares Investor Evenings is going to Manchester, we will showcase four leading companies bringing them together in one room for one evening only.
Directors present their latest plans regarding development and growthAn opportunity to talk directly to the companies and personally put forward your questionsThe chance to network with other attendees over drinks and canapés - private investors, wealth managers, private client brokers, fund managers and financial institutionsTuesday 31st March 2015
Venue:Lancashire County Cricket Club, Manchester, Emirates Old Trafford, Talbot Road, Manchester, M16 0PX
Event Timings:18.00 | Registration and coffee | |
18.30 | Presentations • Neil O'Brien, CEO - Alkane Energy (ALK:AIM) • Andrew Newland, CEO - Angle (AGL:AIM) • Dr Satu Vainikka, Chief Executive Officer - Valirx (VAL:AIM) • Martin Perrin, Chief Financial Officer - Vipera (VIP:AIM) | |
20.30 | Drinks reception and canapés | |
21.30 | Close |
![]() | Alkane Energy is one of the UK’s fastest growing independent power generators. The Company operates mid-sized 'gas to power' electricity plants providing both predictable and fast response capacity to the grid. Alkane now has a total of 140MW of installed generating capacity and an electricity grid capacity of 160MW. |
![]() | ANGLE plc is a specialist medtech company listed on the London Stock Exchange AIM market (AGL.L). ANGLE's lead product is the Parsortix micro-fluidic cell separation device, which can capture very rare circulating tumour cells (CTCs) in cancer patient blood – even when there is less than one CTC in one billion healthy cells. In December 2013, ANGLE secured CE Mark regulatory authorisation for the clinical market in 2013 and FDA approval is planned for 2014. The primary application is the capture of circulating tumour cells (CTCs) in patient blood for: • Early detection of cancer;• Personalised cancer treatment;• Monitoring of cancer patients during treatment; and• Post-treatment monitoring of cancer patients in remission. |
![]() | Valirx Plc is an oncology-focussed Biopharmaceutical Company, developing treatments and diagnostics. Technologies are selected by using rigorous clinical and commercial processes to address unmet market needs. Clinical lead product is VAL201, a peptide for prostate cancer with follow-on indications in ovarian and breast cancers and endometriosis. Product VAL401, is a small molecule reformulation for lung cancers. The Company’s proprietary technology platform, GeneICE, enables selective silencing of rebellious genes’ inappropriate activity. VAL101, the first GeneICE therapeutic, targets and reduces expression of Bcl-2, implicated in about half of cancers. GeneICE extension to neurology and inflammatory diseases will follow. A novel diagnostic, the Nav3 system, detects pre-cancerous, cancerous and metastatic cells in tissue samples even before a tumour forms; indicating potential malignant formation. |
![]() | Vipera is a leading provider of mobile financial services platforms. The Vipera platform provides the easiest, fastest, most cost-effective way to develop and operate mobile data services. Solutions powered by Vipera run today on more than 500,000 phones, on hundreds of mobile networks in many countries. Founded in 2005, Vipera has offices in Zurich, Milan and London. |
The evening exposes investors to companies across various sectors. Perfect for existing investors as well as those looking for new investment opportunities.
Wednesday 15th February 2017
Venue:Radisson Blu Hotel Edinburgh, 80 High Street, The Royal Mile, Edinburgh, EH11TH
Event Timings:17.30 | Registration and coffee | |
17.55 | Presentations • Alex Borrelli, Chairman & CEO - BMR (BMR) • Jeremy Hawke, Mining & Operations Director - BMR (BMR) • Ed Molyneux, CEO - FreeAgent (FREE) • Michael Hunt, CFO - ReNeuron Group (RENE) • Richard Clemmey, MD - Tertiary Minerals (TYM) • Martin Perrin, CFO - Vipera (VIP) | |
20.45 | Drinks reception and canapés | |
21.45 | Close |
![]() | AJ Bell Youinvest is a multi-award winning provider of SIPPs, stocks and shares ISAs, Junior ISAs, Junior SIPPs and share dealing accounts. We offer customers access to a market leading range of investment options, including: shares, funds, ETFs, investment trusts and much more. Our online dealing service starts from just £4.95 and never costs more than £9.95 per deal. |
![]() | BMR has successfully developed a proprietary acid/brine leach process that enables it to achieve high metal recoveries from the different tailings deposits. BMR Group PLC is listed on AIM under the ticker BMR. The Company is focused on the recovery of lead and zinc from the tailings deposits of Zambia’s oldest mine at Kabwe. |
![]() | FreeAgent launched in 2007, hewn from the frustration that managing company finances was just too damn hard for most small businesses and freelancers. Since then we’ve doggedly stuck to our mantra of demystifying accounting and redefining the relationship people have with their finances. Ambitious? Sure. Crazy? Quite possibly, but we think it might just work. We’ve won some important awards over the years, but we’re most proud of the lovely things our users say about us, and the super smart and friendly team we’ve built. We’re based in the Scottish capital Edinburgh, recently described as “Probably the most beautiful city we have ever seen” by The Black Eyed Peas! High praise indeed.
|
![]() | ReNeuron is a leading, clinical-stage cell therapy development business. Based in the UK, its primary objective is the development of novel cell-based therapies targeting areas of significant unmet or poorly met medical need. ReNeuron has used its unique stem cell technologies to develop cell-based therapies for significant disease conditions where the cells can be readily administered “off-the-shelf” to any eligible patient without the need for additional immunosuppressive drug treatments. The Company’s therapeutic candidates for stroke disability and critical limb ischaemia are in clinical development and its cell-based treatment for blindness-causing diseases of the retina is currently in pre-clinical development. ReNeuron is also advancing a proprietary platform technology to exploit nanoparticles (exosomes) secreted by stem cells as potential new drug candidates targeting indications in tissue repair, fibrosis and cancer. |
![]() | Tertiary Minerals plc (ticker symbol 'TYM') is an AIM-traded mineral exploration and development company building a significant strategic position in the fluorspar sector. Fluorspar is an essential raw material in the chemical, steel and aluminium industries with no large scale commercial alternative, or recycling available. Tertiary controls two significant Scandinavian projects (Storuman in Sweden and Lassedalen in Norway) and a large deposit of strategic significance in Nevada USA (MB Project) from which the Company is planning to produce premium grade fluorspar - acid-spar.
|
![]() | Vipera is a leading provider of mobile financial services platforms. The Vipera platform provides the easiest, fastest, most cost-effective way to develop and operate mobile data services. Solutions powered by Vipera run today on more than 500,000 phones, on hundreds of mobile networks in many countries. Founded in 2005, Vipera has offices in Zurich, Milan and London. |